BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 21, 2009
 |  BioCentury  |  Finance

Swiss on a roll

The Swiss biotech space hotted up last week as two of its leading funds, run by HBM Partners, picked up more than $200 million in a couple of trade sale exits, while Evolva S.A. announced plans to raise a minimum of CHF25 million ($24 million) in a private round prior to reverse merging with Arpida Ltd.

The HBM BioVentures and BioCapital funds are poised to return a substantial amount of cash to their investors following the sale of portfolio companies EsbaTech AG and Brahms AG. According to HBM CEO Andreas Wicki, the sale of EsbaTech's ophthalmology assets to Alcon Inc. provides the Swiss antibody company's investors a 1.6X return up front and the potential of a further 4.5X if milestones are achieved.

The sale of molecular diagnostics play Brahms to Thermo Fisher Scientific Inc. yielded a 21.6X return for the funds.

In absolute terms, the exits will provide the HBM funds with more than $200 million and collectively pay back more than the total amount invested by HBM BioCapital so far. The firm has committed capital of $170 million.

Alcon agreed to...

Read the full 911 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >